Transce3nd’s Edwards Lifesciences EW Stock Holding History

Transce3nd’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42	Closed	-$3.29K	–	459
2025 Q2	$3.29K	Hold	42	–	–	﹤0.01%	816
2025 Q1	$3.04K	Sell	42 -270	-87%	-$19.3K	﹤0.01%	810
2024 Q4	$23.1K	Buy	+312	New	+$21.8K	0.01%	521

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Transce3nd's EW Position: Q3 2025 in Review

Transce3nd sold out of Edwards Lifesciences (EW) in Q3 2025, closing a stake of 42 shares — an estimated $3.29K sold.

Transce3nd first reported a position in EW in Q4 2024 and held it in 3 quarters. The position peaked at $23.1K in Q4 2024. 1,254 funds tracked by Wall St. Rank hold EW as of Q3 2025.

Transce3nd reported no remaining Edwards Lifesciences position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 42 Edwards Lifesciences shares in Q3 2025, an estimated $3.29K.
Transce3nd first reported a position in Edwards Lifesciences in Q4 2024 and held it in 3 quarters.
Transce3nd's Edwards Lifesciences position peaked at $23.1K in Q4 2024.
1,254 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.